Nicotinamide Mononucleotide (NMN) for Neurodegeneration
Introduction
Nicotinamide Mononucleotide (Nmn) For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox"> [@mills2016]
| Category | Value | [@yoshino2018]
|---------|-------| [@zhou2024]
| Full Name | Nicotinamide Mononucleotide | [@wang2023]
| Formula | C11H15N2O8P | [@khan2023]
| Molecular Weight | 335.22 Da | [@wu2016]
| NAD+ Precursor | Yes | [@liu2023]
| Clinical Stage | Phase I/II | [@zhang2016]
| Routes | Oral, IV, IP | [@fang2024]
</div>
Overview
flowchart TD
Nicotinamide_Mononucleotide__N["Nicotinamide Mononucleotide NMN for Neurodegener"]
Nicotinamide_Mononucleotide__N["Introduction"]
Nicotinamide_Mononucleotide__N -->|"related to"| Nicotinamide_Mononucleotide__N
style Nicotinamide_Mononucleotide__N fill:#81c784,stroke:#333,color:#000
Nicotinamide_Mononucleotide__N["important"]
Nicotinamide_Mononucleotide__N -->|"related to"| Nicotinamide_Mononucleotide__N
style Nicotinamide_Mononucleotide__N fill:#81c784,stroke:#333,color:#000
Nicotinamide_Mononucleotide__N["component"]
Nicotinamide_Mononucleotide__N -->|"related to"| Nicotinamide_Mononucleotide__N
style Nicotinamide_Mononucleotide__N fill:#81c784,stroke:#333,color:#000
style Nicotinamide_Mononucleotide__N fill:#4fc3f7,stroke:#333,color:#000
...Nicotinamide Mononucleotide (NMN) for Neurodegeneration
Introduction
Nicotinamide Mononucleotide (Nmn) For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox"> [@mills2016]
| Category | Value | [@yoshino2018]
|---------|-------| [@zhou2024]
| Full Name | Nicotinamide Mononucleotide | [@wang2023]
| Formula | C11H15N2O8P | [@khan2023]
| Molecular Weight | 335.22 Da | [@wu2016]
| NAD+ Precursor | Yes | [@liu2023]
| Clinical Stage | Phase I/II | [@zhang2016]
| Routes | Oral, IV, IP | [@fang2024]
</div>
Overview
Mermaid diagram (expand to render)
Nicotinamide mononucleotide (NMN) is a nucleoside ribomonophosphate that serves as a key intermediate in the biosynthesis of nicotinamide adenine dinucleotide (NAD+)[@imai2014]. NAD+ is an essential coenzyme for numerous enzymatic reactions involved in cellular metabolism, DNA repair, and stress responses. NMN supplementation has emerged as a promising strategy to restore NAD+ levels in aging and neurodegenerative diseases.
Biochemistry
NAD+ Biosynthesis Pathways
NMN is synthesized in the body through multiple pathways:
| Pathway | Starting Material | Enzyme | Location |
|---------|------------------|--------|----------|
| Salvage pathway | Nicotinamide | NAMPT | Cytosol |
| Preiss-Handler pathway | Nicotinic acid | NAPRT | Cytosol |
| de novo pathway | Tryptophan | Multiple | Mitochondria |
NMN to NAD+ Conversion
NMN is directly converted to NAD+ by the enzyme NMN adenylyltransferase (NMNAT):
NMN + ATP → NAD+ + PPi (2 molecules)
This reaction occurs in multiple tissues, including the brain, making NMN an efficient NAD+ precursor.
Neuroprotective Mechanisms
Sirtuin Activation
NMN increases NAD+ levels, which in turn activates sirtuin enzymes:
| Sirtuin | Function | Brain Relevance |
|---------|----------|-----------------|
| SIRT1 | Deacetylase | Neuroprotection, circadian rhythm |
| SIRT3 | Mitochondrial | Mitochondrial function |
| SIRT6 | Genome stability | DNA repair |
Mitochondrial Protection
- Enhanced biogenesis: PGC-1α activation via SIRT1
- Improved Complex I activity: Restored electron transport
- Reduced [ROS](/entities/reactive-oxygen-species): Enhanced antioxidant defenses
DNA Repair
- PARP activation: NAD+-dependent DNA repair
- Reduced DNA damage: Accumulated damage contributes to neurodegeneration
Neuroinflammation Reduction
- Microglial modulation: Reduced pro-inflammatory phenotype
- SASP attenuation: Lower inflammatory cytokine secretion
Clinical Evidence
Alzheimer's Disease
| Trial | Phase | Dose | Duration | Outcome |
|-------|-------|------|----------|---------|
| Various | I | 100-500mg | 2-4 weeks | Safe, well-tolerated |
| Preclinical | N/A | 100-300mg/kg | Months | Improved cognition |
Key Findings:
- Increased blood NAD+ levels
- Improved cognitive function in animal models
- Reduced amyloid plaques in [APP](/entities/app-protein)/PS1 mice
Parkinson's Disease
| Study | Model | Outcome |
|-------|-------|---------|
| NMN in MPTP mice | Preclinical | Protected dopaminergic [neurons](/entities/neurons) |
| NMN + exercise | Preclinical | Additive benefits |
| NMN + CoQ10 | Preclinical | Synergistic neuroprotection |
Other Neurodegenerative Conditions
- ALS: Extended survival in SOD1 mouse model
- Stroke: Reduced infarct size, improved recovery
- Traumatic brain injury: Improved functional outcomes
Pharmacokinetics
Absorption
| Parameter | Value |
|-----------|-------|
| Oral bioavailability | ~40-60% |
| Tmax (oral) | 2-3 hours |
| Half-life | ~2-3 hours |
Brain Penetration
NMN crosses the [blood-brain barrier](/entities/blood-brain-barrier) through specific transporters:
- Slc12a8: NMN-specific transporter in brain
- Expression increases with age, potentially compensatory
Dosing Recommendations
| Population | Dose | Frequency |
|------------|------|-----------|
| Human studies | 100-500mg | Daily |
| Preclinical | 100-300mg/kg | Daily |
Safety Profile
Adverse Effects
- Generally well-tolerated
- Mild: GI discomfort at high doses
- No serious adverse events in clinical trials
Contraindications
- Pregnancy (insufficient data)
- Lactation (insufficient data)
See Also
- [NAD+ Boosters for Neurodegeneration](/nad+-boosters-for-neurodegeneration)
- [NAD+ Metabolism in Neurodegeneration](/nad+-metabolism-in-neurodegeneration)
- [Mitochondrial Dysfunction in Alzheimer's](/mechanisms/mitochondrial-dysfunction-alzheimers)
- [Sirtuins and Longevity](/mechanisms/sirtuins-aging)
Background
The study of Nicotinamide Mononucleotide (Nmn) For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
Combination Therapy Potential
NMN + Other NAD+ Precursors
| Combination | Potential Benefit | Evidence Level |
|-------------|------------------|----------------|
| NMN + NR | Complementary pathways | Preclinical |
| NMN + Resveratrol | SIRT1 activation | Preclinical |
| NMN + PARP inhibitors | Preserved NAD+ | Theoretical |
NMN + Other Neuroprotective Agents
| Agent | Interaction | Potential |
|-------|------------|-----------|
| GLP-1 agonists | Complementary mechanisms | Promising |
| Spermidine | Autophagy enhancement | Preclinical |
| Lithium | GSK3β inhibition | Exploratory |
Research Directions
Ongoing Clinical Trials
| Trial | Phase | Condition | Primary Outcome |
|-------|-------|-----------|-----------------|
| Various | I | Healthy aging | Safety, PK |
| Various | II | MCI | Cognitive function |
| Various | II | Parkinson's | Motor function |
Biomarker Development
Key biomarkers being tracked in NMN trials:
- NAD+ levels in blood and CSF
- Sirtuin activity markers
- Mitochondrial function indicators
- Inflammatory markers (IL-6, TNF-α)
- Cognitive performance measures
Regulatory Status
Current Status
- FDA: Not approved as of 2024
- Status: Available as dietary supplement in some countries
- Research use: Phase I/II clinical trials ongoing
- Quality concerns: Variable supplement quality
Future Directions
References
[Imai S, Guarente L, NAD+ and sirtuins in aging and disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25175627/)
[Mills KF, Yoshida S, Stein LR, et al, Long-term administration of nicotinamide mononucleotide improves mitochondrial function and cognitive behavior (2016)](https://pubmed.ncbi.nlm.nih.gov/28068222/)
[Yoshino J, Baur JA, Imai SI, NAD+ intermediates: the biology and therapeutic potential of NMN and NR (2018)](https://pubmed.ncbi.nlm.nih.gov/29458440/)
Zhou CC, Yang X, Liu J, et al, NMN ameliorates mitochondrial dysfunction in a mouse model of Alzheimer's disease (2024)
Wang X, Hu X, Yang Y, et al, Nicotinamide mononucleotide protects against dopaminergic neuron loss in Parkinson's disease model (2023)
Khan NA, Auranen M, Paetau I, et al, Effective treatment of mitochondrial disease with a cell-rescuing NAD+ precursor (2023)
Wu LE, Sinclair DA, Restoring NAD+ with NMN (2016)
Liu D, Pitta M, Jiang H, et al, Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice (2023)
Zhang H, Ryu D, Wu Y, et al, NAD+ repletion improves mitochondrial and stem cell function and enhances life span (2016)
Fang EF, Kasselman MJ, de L, et al, NAD+ replenishment improves mitochondrial function and reverses aging (2024)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
- [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
Related Analyses:
- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
- [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
- [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
- [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄